Wells Fargo analyst Jacob Hughes named Revance Therapeutics (RVNC) and Amphastar Pharmaceuticals (AMPH) his top ideas for 2020 in the Specialty Pharmaceuticals space.

For Revance, the analyst believes the recent filler acquisition is "highly synergistic" while a "slew of pipeline catalysts are upcoming."

For Amphastar, he says the Primatene launch is progressing well and that "several" pipeline catalysts will drive value.

For a near-term trade, Hughes likes Emergent BioSolutions (EBS) for a potentially favorable ruling in the Narcan patent litigation per his patent consultant feedback.

The analyst this morning also upgraded Bausch Health Companies (BHC) to Equal Weight from Underweight and downgraded Allergan (AGN) to Equal Weight from Overweight. He also lowered his price target for Equal Weight-rated Evolus (EOLS) to $12 from $15, raised his price target for Overweight-rated Jazz Pharmaceuticals (JAZZ) to $189 from $186, raised his price target for Overweight-rated Karuna Therapeutics (KRTX) to $137 from $106, raised his price target for Equal Weight-rated Perrigo (PRGO) to $63 from $51, raised his price target for Overweight-rated Revance to $35 from $20, raised his price target for Equal Weight-rated Teva (TEVA) to $10 from $8, raised his price target for Equal Weight-rated Mallinckrodt (MNK) to $6 from $3, and raised his price target for Overweight-rated Osmotica Pharmaceuticals (OSMT) to $8 from $7.